Guangwen Yuan

机构：Chinese Academy of Medical Sciences & Peking Union Medical College, National Cancer Center · ORCID：0000-0001-8480-3596

发表论文 63 篇 · 总被引 440 次 · h-index 11

代表论文

• A proteogenomic analysis of cervical cancer reveals therapeutic and biological insights (2024 · Nature Communications · 被引 25)
• Evaluation of the effectiveness and safety of disitamab vedotin in HER2-expressing 2L recurrent or metastatic cervical cancer (r/mCC): Interim results of RC48-C018. (2024 · Journal of Clinical Oncology · 被引 11)
• AdvanTIG-202: Phase 2 open-label, two-cohort multicenter study of ociperlimab plus tislelizumab and tislelizumab alone in patients with previously treated recurrent or metastatic cervical cancer (2025 · Gynecologic Oncology · 被引 7)
• Efficacy and safety of paclitaxel liposome versus paclitaxel in combination with carboplatin in the first-line chemotherapy for ovarian cancer: a multicenter, open-label, non-inferiority, randomized controlled trial (2024 · Journal of the National Cancer Center · 被引 7)
• Prevalence and Prognostic Relevance of Homologous Recombination Repair Gene Mutations in Uterine Serous Carcinoma (2022 · Cells · 被引 7)
• Outcomes of secondary cytoreductive surgery in patients with platinum-sensitive recurrent ovarian cancer progressed after prior poly (adenosine diphosphate-ribose) polymerase inhibitors: A retrospective cohort study (2024 · European Journal of Surgical Oncology · 被引 4)